Flores-Rivera OI, Neri-Maldonado R, Díaz-Ponce-Medrano JA, Barragán-Hernández IJ, Hernández-Trujillo E

Idioma: Español
Referencias bibliográficas: 24
Paginas: 386-391
Archivo PDF: 189.36 Kb.

RESUMEN

El concentrado de complejo protrombínico (CCP) es un medicamento purificado con actividad hemostática derivada del plasma. El CCP está recomendado como una alternativa en relación al uso del plasma fresco congelado (PFC) y factor VII activado recombinante (rfVIIa) para el tratamiento de la hemorragia que pone en riesgo la vida debido al uso de antagonistas de la vitamina K (AVK). Se considera un fármaco seguro en indicaciones recomendadas y con dosis adecuadas y las precauciones conocidas para su empleo, con un efecto de reversión óptimo. El objetivo de este trabajo es dar a conocer las características generales del CCP, sus principales indicaciones, modo de empleo y áreas de oportunidad en la anestesiología y la medicina intensiva.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke. 2011;42:2431-2435.

2. Chapman SA, Irwin ED, Beal AL, Kulinski NM, Hutson KE, Thorson MA. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin. Ann Pharmacother. 2011;45:869-875.

3. Vigué B. Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe hemorrhage, from theory to practice. Crit Care. 2009;13:209.

4. Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis. 2010;29:171-181.

5. Taberner DA, Thomson JM, Poller L. Comparison of prothrombin complex concentrate and vitamin K1 in oral anticoagulant reversal. Br Med J. 1976;2:83-85.

6. Samama CM. Prothrombin complex concentrates: a brief review. Eur J Anesthesiol. 2008;25:784-789.

7. Liumbruno G, Bernnardello F, Lattanzio A, Piccoli P, Rossetti G. Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. Blood Transfus. 2009;7:325-334.

8. Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract. 2008;82:1614-1622.

9. Patanwala AE, Acquisto NM, Erstad BL. Prothrombin complex concentrate for critical bleeding. Ann Pharmacother. 2011;45:990-999.

10. Páramo JA, Panizo E, Pegenaute C, Lecumberri R. Coagulación 2009: una visión moderna de la hemostasia. Rev Med Univ Navarra. 2009;53:19-23.

11. Kor DJ, Stubbs JR, Gajic O. Perioperative coagulation management fresh frozen plasma. Best Prac Res Clin Anesthesiol. 2010;24:51-64.

12. Gatt A, Riddell A, van Veen JJ, Kitchen S, Tuddenham EG, Makris M. Optimizing warfarin reversal: an ex-vivo study. J Thromb Hemostas. 2009;7:1123-1127.

13. Colomina MJ, Díez Lobo A, Garutti I, Gómez-Luque A, Llau JV, Pita E. Perioperative use of prothrombin complex concentrates. Minerva Anestesiol. 2012;78:358-368.

14. Schulman S. Clinical practice. Care of patients receiving long term anticoagulant therapy. N Engl J Med. 2003;349:675-683.

15. Goodnough LT. A reappraisal of plasma, prothrombin complex concentrates, and recombinant Factor VIIa in patient blood management. Crit Care Clin. 2012;28:413-426.

16. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;83:137-143.

17. Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care. 2008;12:R105.

18. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.

19. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-1579.

20. Nitzki D, Wozniak I, Caprini J. Current state of knowledge on oral anticoagulant reversal using procoagulant factors. Ann Pharmacother. 2013;47:841-855.

21. Dabbagh O, Oza A, Prakash S, Sunna R, Saettele TM. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest. 2010;137:1145-1149.

22. Lorenz R, Kienast J, Otto U, Egger K, Kiehl M, Schreiter, et al. Efficacy and safety of a prothrombin complex concentrate with two virus inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol. 2003;15:15-20.

23. Malone DL, Hess JR, Fingerhut A. Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. J Trauma. 2006;60:S91-S96.

24. Dickneite G, Pragst I. Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model. Br J Anaesth. 2009;102:345-354.